Tue, Sep 2, 2014, 1:26 AM EDT - U.S. Markets open in 8 hrs 4 mins

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

galaberge 80 posts  |  Last Activity: Aug 31, 2014 9:35 PM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • galaberge galaberge Aug 31, 2014 9:35 PM Flag

    ugt_92251-Excellent post

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    505 b2

    by don_quixote123456 Aug 29, 2014 10:42 PM
    galaberge galaberge Aug 31, 2014 7:34 PM Flag

    When you have a patent it's public information. So anybody can see medicinal ingredients and their associated patents, the patent expiry dates and other related information established in accordance with the Patented Medicines. But nobody can use it until expiration of the patent.

    As I said in previous post "in fact, many generic drugs are made in the SAME MANUFACTURING plants as brand name drug products." So it's very simple to make it.

    Do your DD and you will learn a lot about "who is missing the boat"

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Teva needs Trimesta

    by luckymonkey77 Aug 31, 2014 6:11 PM
    galaberge galaberge Aug 31, 2014 7:00 PM Flag

    I can't agree with you because the NEW and IMPROVED Copaxone (with Estriol) will be marketed under the same brand name "Copaxone" and so will be sold at the same price of the actual Copaxone (likely more expensive because more potent)

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    505 b2

    by don_quixote123456 Aug 29, 2014 10:42 PM
    galaberge galaberge Aug 31, 2014 6:49 PM Flag

    My answer was for don_quixote123456 ! But I can answer your questions about generic of Copaxone. First go to the following link to understand how aa géneric is made ; the link is "fdaDOTgov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm167991DOThtm" Don't forget to replace the words "DOT" by a real dot= .

    You will see that it's very easy to copy a drug and it take only several weeks to produce/market it because "in fact, many generic drugs are made in the SAME MANUFACTURING plants as brand name drug products."

    Second question "How will a license for Trimesta, an oral drug, help Teva protect the patent on its injectable, copaxone?"

    Very easy to answer. Because the PATENT owned by Synthetic ( #US 8372826 B2) is for a COMBINATION as released by Synthetic Biologics under the name "Synthetic Biologics Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple Sclerosis" See the PR dated "ROCKVILLE, Md., April 4, 2013 /PRNewswire" or go to the following link "syntheticbiologicsDOTcom/2013-04-04-Synthetic-Biologics-Announces-Issuance-of-U-S-Patent-Covering-Combination-of-Estriol-and-Copaxone-for-Multiple-Sclerosis"

    In fact this patent was INTENTIONALLY done like that to attract TEVA or another company to have a partnership and have immediate money for many years.

    The REALITY is with Estriol we DON'T need any other secondary product (Copaxone or anything else). Estriol is THE drug for MS.

    So if TEVA wants to protect her market for at least another 12 years and have a MORE POTENT Copaxone to sell (due to the Estriol) it makes sense to partner with Synthetic.

    Have a good day.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    505 b2

    by don_quixote123456 Aug 29, 2014 10:42 PM
    galaberge galaberge Aug 31, 2014 2:36 PM Flag

    Back from a week vacation and I am happy for all longs with SYN.

    To answer your question I have found this:

    The 2 links : momentapharmaDOTcom/pipeline/m356DOTphp

    and https://finance.yahoo.com/news/momenta-sandozs-generic-copaxone-accepted-182002349.html
    and the text:

    M356 is designed to be a generic version of Copaxone (glatiramer acetate), a drug consisting of a complex mixture of polypeptide chains and indicated for reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis is a devastating chronic disease of the central nervous system characterized by inflammation and neurodegeneration. RRMS, defined by inflammatory attacks on the protective coating of neurons (myelin) and characterized by intermittent bouts of symptoms, is the most common disease course at the time of diagnosis. Copaxone is among the leading products marketed for treatment of RRMS. It works by stopping the body from damaging its own nerve cells (myelin).

    Under our 2006 collaboration with Sandoz, Momenta and Sandoz agreed to jointly develop, manufacture, and commercialize M356, among other products. Characterizing Copaxone represents another significant technical challenge for generic manufacturers given its complex mixture of polypeptide chains of various lengths and sequences. Momenta is addressing this challenge with our core characterization and process engineering capabilities to develop and manufacture M356. The ANDA for M356 is currently under FDA review.

    I believe TEVA or another company will partner with SYN after the presentation of Dr Voskhul

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Trimesta Stand-alone Will Work!

    by tina_bridgett50 Aug 14, 2014 9:52 AM
    galaberge galaberge Aug 24, 2014 4:58 PM Flag

    All what you say is incorrect. You have not made a DD and so your figures are totally false. Sorry.

    I can come back with real figures

    Sentiment: Strong Buy

  • Reply to

    Incredible number of September catalysts.

    by godawgs_428 Aug 21, 2014 12:27 PM
    galaberge galaberge Aug 21, 2014 4:33 PM Flag

    Godawgs_428-You are very well aware of SYN.

    I like people who are doing their DD with method and rationality. You're a good collaborator on every message board.

    Let's go for the big ride in 2014.

    Hope everyone will take the time to read the last CC transcript and the previous ones.

    Have a good day.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Aug 20, 2014 11:08 PM Flag

    Thanks for your comment. Have a good evening

    Sentiment: Strong Buy

  • galaberge galaberge Aug 20, 2014 2:58 PM Flag

    Some of the new findings of SYN will be linked with the patent of Dr Rhonda R. Voskuhl called "Estriol therapy for multiple sclerosis and other autoimmune diseases" ?

    Just follow the link : googleDOTcom/patents/US6936599

    Very interesting to have her with SYN

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Aug 19, 2014 10:29 AM Flag

    You are right in what you say.

    Sentiment: Strong Buy

  • galaberge galaberge Aug 19, 2014 8:55 AM Flag

    A lot of naysayers this morning with their thumbs down ! Good sign !

    Sentiment: Strong Buy

  • .....on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

    Synthetic Biologics' Senior Vice President, Research & Development, Mike Kaleko, M.D., Ph.D., will present a late-breaking poster related to the Company's C. difficile program. The poster will be available for viewing in Exhibit Hall A on Saturday, September 6, from 12:00pm to 2:00pm Eastern Time, as part of the "Agents Targeting Clostridium difficile" session.

    "We are thrilled to have the opportunity to present research from our novel C. difficile program at ICAAC. This conference is known for its high academic standards and draws the infectious disease field's foremost leaders. We look forward to presenting our findings that support the development of our prophylactic to protect the GI microflora from the effects of certain IV antibiotics for the prevention of C. difficile infection," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "This scientific presentation is very relevant, as we continue to advance our innovative C. difficile program toward clinical trials during 2014."

    Good news continue to come

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Aug 14, 2014 3:41 PM Flag

    You are short-sighted. It should not be difficult to calculate your penny-gains if any shorty at the end of the day!

    Sentiment: Strong Buy

  • galaberge galaberge Aug 14, 2014 3:20 PM Flag

    Link :seekingalphaDOTcom/article/2423855-synthetic-biologics-syn-ceo-jeff-riley-on-q2-2014-results-earnings-call-transcript

    Sentiment: Strong Buy

  • Read it and learn why SYN is the best stock !

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Riley hit a Home Run

    by mdr0418 Aug 14, 2014 9:19 AM
    galaberge galaberge Aug 14, 2014 9:22 AM Flag

    Really a very informative CC on "what's next" on the near-medim term.

    And as you say it's time to board the train.

    Long and strong SYN

    Sentiment: Strong Buy

  • ....at Grand Hyatt New York Hotel, New York City

    This event will be accessible via live webcast, to be made available on Synthetic Biologics' website.

    Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

    Dr. Mark Pimentel is Director, GI Motility Program and Laboratory, and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, California. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in IBS, and the relationship between gut flora composition and human disease.

    Also Synthetic Biologics' CEO, Jeffery Riley, and Joseph Sliman, M.D., M.P.H., Senior Vice President, Clinical & Regulatory Affairs, will provide an overview of the anticipated clinical and regulatory pathway for SYN-010 to reduce the impact of methane producing organisms on C-IBS, including plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014.

    Don't forget : This event will be accessible via live webcast, to be made available on Synthetic Biologics' website.

    More and more good news are coming and reflect how the management of SYN wants to keep informed all the shareholders. It's a positive sign to have this privileged relationship between the company and her shareholders.

    Long and strong SYN

    Sentiment: Strong Buy

  • ....on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

    Synthetic Biologics' academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin's McKetta Department of Chemical Engineering will present Synthetic Biologics' SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the "Neonatal Infections and the Case for Maternal Immunization" session.

    "We are pleased to have Dr. Maynard showcase the research supporting the clinical development of SYN-005 amongst esteemed academic peers, and the infectious disease field's foremost leaders at ICAAC, a conference with high academic standards and commitment to providing an overview of the state of infection control and prevention on a global scale," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "This scientific presentation is timely, as we continue to advance our innovative Pertussis program toward clinical-stage development in early 2015."

    More and more good news coming as promised.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Aug 10, 2014 7:37 PM Flag

    Jrdelaine-Based on what I have seen in the overall market and the PPS of many small biotech stocks I see we are already in a correction phase; this correction has started around March 2014 and will affect all the stocks not presenting a concrete basis, and a feasible pipeline of potential products with a strong mngt to achieve/close the researches to have positive results such as real products on the market. IMO the time is over for pure speculation with biotech stocks. We are now in the mode of "We want to see results and the money NOW". No biotech will resist very long on the stock market with frivolous statements, "trial and errors", and poor mngt not personally involved heavily in their company and giving shareholders something that is not interesting, or stating something very close to the truth while it's not, or just #$%$. These companies will be punished strongly.

    Coming back to SYN Randal Kirk with 44%+ of the company is pretty involved, and has a proven record of successes in biotech companies (a self-made fortune from biopharma of $3+Billion); if we add the strong needed pipeline of SYN close to start to deliver factual results, I believe the PPS will soon reflect a very interesting reality.

    So, to summarise, I think only reliable companies, and SYN is one of these excellent ones, will give strong gains to their shareholders in spite of the overall downside market. For the other ones, the speculation time will come back in 10 years.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Aug 8, 2014 6:29 AM Flag

    The news will be so positive they can't miss their announcement ! All the researches made are about to be revealed.

    Have a good day.

    Long and strong SYN

    Sentiment: Strong Buy

IRWD
12.94+0.29(+2.29%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exelixis, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Splunk, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT